Gore Christopher J, Parisotto Robin, Ashenden Michael J, Stray-Gundersen Jim, Sharpe Ken, Hopkins Will, Emslie Kerry R, Howe Chris, Trout Graham J, Kazlauskas Rymantas, Hahn Allan G
Australian Institute of Sport, Adelaide, SA 5022, Australia.
Haematologica. 2003 Mar;88(3):333-44.
We previously developed blood tests that were introduced at the Sydney 2000 Olympic Games to identify athletes injecting recombinant human erythropoietin (rHuEPO). The aim of this study was to re-analyse our existing database to develop models with heightened sensitivity, using wherever possible blood parameters measurable with appropriate standards of analytical performance.
The principal database for this study was derived from a double-blind trial in which 57 recreational athletes were administered either rHuEPO or placebo. Standard discriminant analysis was used to derive two ON models (ON-hes and ON-he) and two OFF models (OFF-hr and OFF-hre) sensitive to accelerated and decelerated erythropoiesis respectively, utilising concentrations of hemoglobin (h), erythropoietin (e) and serum transferrin receptor (s), as well as percent reticulocytes (r). The ability of our models to detect rHuEPO administration was assessed by comparing model scores of subjects in the administration trial with the model scores of 1152 elite athletes from 12 countries.
The ability of the new models to detect rHuEPO administration was generally higher than that of our previous models, particularly during phases when low doses of rHuEPO were used, and after injections had ceased. INTERPRETATION AND CONCLUSIONS. The increased stability of the new blood parameters facilitates transport of samples to central laboratories, and the heightened sensitivity of the new models makes them better than existing models for federations wishing to screen samples for urine testing and to identify and target suspect athletes for out-of-competition testing. However procedures should be incorporated that respect an elevated model score caused by genetic, health or environmental circumstances.
我们此前开发了血液检测方法，并在2000年悉尼奥运会上应用，以识别注射重组人促红细胞生成素（rHuEPO）的运动员。本研究的目的是重新分析我们现有的数据库，尽可能使用具有适当分析性能标准可测量的血液参数，开发出具有更高灵敏度的模型。
本研究的主要数据库来自一项双盲试验，57名业余运动员分别接受了rHuEPO或安慰剂。使用标准判别分析得出两个分别对红细胞生成加速和减速敏感的ON模型（ON-hes和ON-he）以及两个OFF模型（OFF-hr和OFF-hre），利用血红蛋白（h）、促红细胞生成素（e）、血清转铁蛋白受体（s）的浓度以及网织红细胞百分比（r）。通过比较给药试验中受试者的模型分数与来自12个国家的1152名精英运动员的模型分数，评估我们模型检测rHuEPO给药的能力。
新模型检测rHuEPO给药的能力总体上高于我们之前的模型，特别是在使用低剂量rHuEPO的阶段以及注射停止后。解释与结论：新血液参数稳定性的提高便于将样本运输到中心实验室，新模型更高的灵敏度使其比现有模型更适合联合会对样本进行尿液检测筛查，并识别和针对疑似运动员进行赛外检测。然而，应纳入相关程序，以考虑由遗传、健康或环境因素导致的模型分数升高情况。
